Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
12 Feb 2024
12 Feb 2024
Historique:
received:
06
03
2023
accepted:
29
01
2024
medline:
13
2
2024
pubmed:
13
2
2024
entrez:
12
2
2024
Statut:
epublish
Résumé
Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of chemotherapy on CAF populations remains poorly understood. Here we address this question in high-grade serous ovarian cancer (HGSOC), in which we previously identified 4 CAF populations. While the global content in stroma increases in HGSOC after chemotherapy, the proportion of FAP
Identifiants
pubmed: 38346978
doi: 10.1038/s41467-024-45595-3
pii: 10.1038/s41467-024-45595-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1312Subventions
Organisme : Institut National Du Cancer (French National Cancer Institute)
ID : INCa-DGOS-9963
Organisme : Institut National Du Cancer (French National Cancer Institute)
ID : INCa-11692
Organisme : Institut National Du Cancer (French National Cancer Institute)
ID : INCa_16086
Organisme : Institut National Du Cancer (French National Cancer Institute)
ID : INCa_16101
Informations de copyright
© 2024. The Author(s).
Références
Coleridge, S. L. et al. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst. Rev. 2019, CD005343 (2019).
pubmed: 31684686
pmcid: 6822157
Coleman, R. L. et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 18, 779–791 (2017).
pubmed: 28438473
pmcid: 5715461
doi: 10.1016/S1470-2045(17)30279-6
Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949–1961 (2017).
pubmed: 28916367
pmcid: 5901715
doi: 10.1016/S0140-6736(17)32440-6
Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017).
pubmed: 28754483
doi: 10.1016/S1470-2045(17)30469-2
Swisher, E. M. et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 18, 75–87 (2017).
pubmed: 27908594
doi: 10.1016/S1470-2045(16)30559-9
Moore, K. et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 379, 2495–2505 (2018).
pubmed: 30345884
doi: 10.1056/NEJMoa1810858
Wang, H., Xu, T., Zheng, L. & Li, G. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. Int. J. Gynecol. Cancer 28, 903–914 (2018).
pubmed: 29561301
pmcid: 5976222
doi: 10.1097/IGC.0000000000001258
Franzese, E. et al. PARP inhibitors in ovarian cancer. Cancer Treat. Rev. 73, 1–9 (2019).
pubmed: 30543930
doi: 10.1016/j.ctrv.2018.12.002
Gadducci, A. et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J. Ovarian Res. 12, 9 (2019).
pubmed: 30691488
pmcid: 6348631
doi: 10.1186/s13048-019-0484-6
Ray-Coquard, I. et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N. Engl. J. Med. 381, 2416–2428 (2019).
pubmed: 31851799
doi: 10.1056/NEJMoa1911361
Chen, F. et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 13, 45 (2015).
pubmed: 25857315
pmcid: 4350882
doi: 10.1186/s12916-015-0278-7
Hansen, J. M., Coleman, R. L. & Sood, A. K. Targeting the tumour microenvironment in ovarian cancer. Eur. J. Cancer 56, 131–143 (2016).
pubmed: 26849037
pmcid: 4769921
doi: 10.1016/j.ejca.2015.12.016
Gentric, G., Mieulet, V. & Mechta-Grigoriou, F. Heterogeneity in cancer metabolism: new concepts in an old field. Antioxid. Redox Signal 26, 462–485 (2017).
pubmed: 27228792
pmcid: 5359687
doi: 10.1089/ars.2016.6750
Curtis, M., Mukherjee, A. & Lengyel, E. The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. Trends Cancer 4, 517–519 (2018).
pubmed: 30064659
doi: 10.1016/j.trecan.2018.06.002
Ghoneum, A., Afify, H., Salih, Z., Kelly, M. & Said, N. Role of tumor microenvironment in ovarian cancer pathobiology. Oncotarget 9, 22832–22849 (2018).
pubmed: 29854318
pmcid: 5978268
doi: 10.18632/oncotarget.25126
Stack, M. S., Nephew, K. P., Burdette, J. E. & K Mitra, A. The tumor microenvironment of high grade serous ovarian cancer. Cancers (Basel) 11, 21 (2019).
doi: 10.3390/cancers11010021
Mhaidly, R. & Mechta-Grigoriou, F. Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies. Semin. Immunol. 48, 101417 (2020).
pubmed: 33077325
doi: 10.1016/j.smim.2020.101417
Peltier, A., Seban, R. D., Buvat, I., Bidard, F. C. & Mechta-Grigoriou, F. Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging. Semin. Cancer Biol. 86, 262–272 (2022).
pubmed: 35489628
doi: 10.1016/j.semcancer.2022.04.008
Vazquez-Garcia, I. et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612, 778–786 (2022).
pubmed: 36517593
pmcid: 9771812
doi: 10.1038/s41586-022-05496-1
Cojocaru, E., Parkinson, C. A. & Brenton, J. D. Personalising Treatment for High-Grade Serous Ovarian Carcinoma. Clin. Oncol. (R. Coll. Radio.) 30, 515–524 (2018).
doi: 10.1016/j.clon.2018.05.008
Hinchcliff, E. et al. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol. Oncol. 151, 407–413 (2018).
pubmed: 30366646
pmcid: 6281778
doi: 10.1016/j.ygyno.2018.10.008
Zhang, G. et al. Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment. Oncol. Lett. 17, 2583–2591 (2019).
pubmed: 30854033
pmcid: 6365948
Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198–5208 (2008).
pubmed: 18698038
doi: 10.1158/1078-0432.CCR-08-0196
Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
doi: 10.1038/nature10166
Mateescu, B. et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat. Med. 17, 1627–1635 (2011).
pubmed: 22101765
doi: 10.1038/nm.2512
Bentink, S. et al. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One 7, e30269 (2012).
pubmed: 22348002
pmcid: 3278409
doi: 10.1371/journal.pone.0030269
Verhaak, R. G. et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123, 517–525 (2013).
pubmed: 23257362
Konecny, G. E. et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl. Cancer Inst. 106, dju249 (2014).
pubmed: 25269487
pmcid: 4271115
doi: 10.1093/jnci/dju249
Gruosso, T. et al. MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. Nat. Commun. 6, 8583 (2015).
pubmed: 26456302
doi: 10.1038/ncomms9583
Batista, L., Bourachot, B., Mateescu, B., Reyal, F. & Mechta-Grigoriou, F. Regulation of miR-200c/141 expression by intergenic DNA-looping and transcriptional read-through. Nat. Commun. 7, 1–17 (2016).
doi: 10.1038/ncomms9959
Zhang, S. et al. Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci. Rep. 5, 16066 (2015).
pubmed: 26530441
pmcid: 4632004
doi: 10.1038/srep16066
Zhang, Z. et al. Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data. Sci. Rep. 6, 26001 (2016).
pubmed: 27184229
pmcid: 4868982
doi: 10.1038/srep26001
Matondo, A. et al. The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer. Sci. Rep. 7, 9689 (2017).
pubmed: 28851888
pmcid: 5575202
doi: 10.1038/s41598-017-08766-5
Fang, F. et al. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs. Cancer Res. 78, 631–644 (2018).
pubmed: 29229600
doi: 10.1158/0008-5472.CAN-17-1492
Macintyre, G. et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat. Genet. 50, 1262–1270 (2018).
pubmed: 30104763
pmcid: 6130818
doi: 10.1038/s41588-018-0179-8
Menghi, F. et al. The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. Cancer Cell 34, 197–210.e195 (2018).
pubmed: 30017478
pmcid: 6481635
doi: 10.1016/j.ccell.2018.06.008
Gentric, G. et al. PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers. Cell Metab. 29, 156–173.e110 (2019).
pubmed: 30244973
pmcid: 6331342
doi: 10.1016/j.cmet.2018.09.002
Gulhan, D. C., Lee, J. J., Melloni, G. E. M., Cortes-Ciriano, I. & Park, P. J. Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nat. Genet. 51, 912–919 (2019).
pubmed: 30988514
doi: 10.1038/s41588-019-0390-2
Kieffer, Y. et al. Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer. Front. Genet. 11, 219 (2020).
pubmed: 32256521
pmcid: 7089941
doi: 10.3389/fgene.2020.00219
Givel, A. M. et al. miR200-regulated CXCL12beta promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat. Commun. 9, 1056 (2018).
pubmed: 29535360
pmcid: 5849633
doi: 10.1038/s41467-018-03348-z
Hu, Z. et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell 37, 226–242 e227 (2020).
pubmed: 32049047
doi: 10.1016/j.ccell.2020.01.003
Zhang, Q., Wang, C. & Cliby, W. A. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer. Gynecol. Oncol. 152, 368–374 (2019).
pubmed: 30448260
doi: 10.1016/j.ygyno.2018.11.014
Izar, B. et al. A single-cell landscape of high-grade serous ovarian cancer. Nat. Med. 26, 1271–1279 (2020).
pubmed: 32572264
pmcid: 7723336
doi: 10.1038/s41591-020-0926-0
Schwede, M. et al. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. Cancer Epidemiol. Biomark. Prev. 29, 509–519 (2020).
doi: 10.1158/1055-9965.EPI-18-1359
Olbrecht, S. et al. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. Genome Med. 13, 111 (2021).
pubmed: 34238352
pmcid: 8268616
doi: 10.1186/s13073-021-00922-x
Deng, Y. et al. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma. Front Immunol. 13, 923194 (2022).
pubmed: 35935940
pmcid: 9354882
doi: 10.3389/fimmu.2022.923194
Ohlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
pubmed: 28232471
pmcid: 5339682
doi: 10.1084/jem.20162024
Bartoschek, M. et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single-cell RNA sequencing. Nat. Commun. 9, 5150 (2018).
pubmed: 30514914
pmcid: 6279758
doi: 10.1038/s41467-018-07582-3
Cremasco, V. et al. FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors. Cancer Immunol. Res. 6, 1472–1485 (2018).
pubmed: 30266714
pmcid: 6597261
doi: 10.1158/2326-6066.CIR-18-0098
Biffi, G. et al. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFbeta to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discov. 9, 282–301 (2019).
pubmed: 30366930
doi: 10.1158/2159-8290.CD-18-0710
Elyada, E. et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov. 9, 1102–1123 (2019).
pubmed: 31197017
pmcid: 6727976
doi: 10.1158/2159-8290.CD-19-0094
Neuzillet, C. et al. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. J. Pathol. 248, 51–65 (2019).
pubmed: 30575030
pmcid: 6492001
doi: 10.1002/path.5224
Dominguez, C. X. et al. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discov. 10, 232–253 (2020).
pubmed: 31699795
doi: 10.1158/2159-8290.CD-19-0644
Friedman, G. et al. Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4(+) and PDPN(+) CAFs to clinical outcome. Nat. Cancer 1, 692–708 (2020).
pubmed: 35122040
doi: 10.1038/s43018-020-0082-y
Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174–186 (2020).
pubmed: 31980749
pmcid: 7046529
doi: 10.1038/s41568-019-0238-1
Sebastian, A. et al. Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer. Cancers (Basel) 12, 1307 (2020).
pubmed: 32455670
doi: 10.3390/cancers12051307
Biffi, G. & Tuveson, D. A. Diversity and Biology of Cancer-Associated Fibroblasts. Physiol. Rev. 101, 147–176 (2021).
pubmed: 32466724
doi: 10.1152/physrev.00048.2019
Wu, S. Z. et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet 53, 1334–1347 (2021).
pubmed: 34493872
pmcid: 9044823
doi: 10.1038/s41588-021-00911-1
Foster, D. S. et al. Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin. Cancer Cell 40, 1392–1406 e1397 (2022).
pubmed: 36270275
pmcid: 9669239
doi: 10.1016/j.ccell.2022.09.015
Toullec, A. et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med. 2, 211–230 (2010).
pubmed: 20535745
pmcid: 3377319
doi: 10.1002/emmm.201000073
Albrengues, J. et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat. Commun. 6, 10204 (2015).
pubmed: 26667266
doi: 10.1038/ncomms10204
Turcotte, M. et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 75, 4494–4503 (2015).
pubmed: 26363007
doi: 10.1158/0008-5472.CAN-14-3569
Leca, J. et al. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J. Clin. Invest. 126, 4140–4156 (2016).
pubmed: 27701147
pmcid: 5096915
doi: 10.1172/JCI87734
Curtis, M. et al. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 29, 141–155.e149 (2019).
pubmed: 30174305
doi: 10.1016/j.cmet.2018.08.007
Gao, Q. et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J. Exp. Med. 216, 688–703 (2019).
pubmed: 30710055
pmcid: 6400537
doi: 10.1084/jem.20180765
Han, Q. et al. Tumor cellfibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer. Int J. Mol. Med. 44, 2245–2255 (2019).
pubmed: 31638162
pmcid: 6844628
Bonneau, C. et al. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. Breast Cancer Res. 22, 76 (2020).
pubmed: 32665033
pmcid: 7362513
doi: 10.1186/s13058-020-01311-9
Pelon, F. et al. Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat. Commun. 11, 404 (2020).
pubmed: 31964880
pmcid: 6972713
doi: 10.1038/s41467-019-14134-w
Shani, O. et al. Fibroblast-Derived IL33 Facilitates Breast Cancer Metastasis by Modifying the Immune Microenvironment and Driving Type 2 Immunity. Cancer Res. 80, 5317–5329 (2020).
pubmed: 33023944
pmcid: 7611300
doi: 10.1158/0008-5472.CAN-20-2116
Asif, P. J., Longobardi, C., Hahne, M. & Medema, J. P. The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis. Cancers (Basel) 13, 4720 (2021).
pubmed: 34572947
doi: 10.3390/cancers13184720
Yue, H. et al. Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer. Gynecol. Oncol. 160, 530–538 (2021).
pubmed: 33317907
doi: 10.1016/j.ygyno.2020.11.026
Monteran, L. et al. Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer. Nat. Commun. 13, 5797 (2022).
pubmed: 36184683
pmcid: 9527249
doi: 10.1038/s41467-022-33598-x
Zou, R. et al. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer. Front. Immunol. 13, 956224 (2022).
pubmed: 36032075
pmcid: 9402225
doi: 10.3389/fimmu.2022.956224
Denton, A. E., Roberts, E. W., Linterman, M. A. & Fearon, D. T. Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells. Proc. Natl Acad. Sci. USA 111, 12139–12144 (2014).
pubmed: 25092322
pmcid: 4143042
doi: 10.1073/pnas.1412910111
Takahashi, H. et al. Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma. Cancer Immunol. Immunother. 64, 1407–1417 (2015).
pubmed: 26201938
doi: 10.1007/s00262-015-1742-0
Ruhland, M. K. et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat. Commun. 7, 11762 (2016).
pubmed: 27272654
pmcid: 4899869
doi: 10.1038/ncomms11762
Yang, X. et al. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. Cancer Res. 76, 4124–4135 (2016).
pubmed: 27216177
doi: 10.1158/0008-5472.CAN-15-2973
Zhang, Y. & Ertl, H. C. Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. Oncotarget 7, 23282–23299 (2016).
pubmed: 26943036
pmcid: 5029626
doi: 10.18632/oncotarget.7818
Cohen, N. et al. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene 36, 4457–4468 (2017).
pubmed: 28368410
pmcid: 5507301
doi: 10.1038/onc.2017.65
Costa, A. et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell 33, 463–479.e410 (2018).
pubmed: 29455927
doi: 10.1016/j.ccell.2018.01.011
Ovarian Tumor Tissue Analysis C. et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 3, e173290 (2017).
doi: 10.1001/jamaoncol.2017.3290
Kieffer, Y. et al. Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer. Cancer Discov. 10, 1330–1351 (2020).
pubmed: 32434947
doi: 10.1158/2159-8290.CD-19-1384
Hornburg, M. et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell 39, 928–944.e926 (2021).
pubmed: 33961783
doi: 10.1016/j.ccell.2021.04.004
Mhaidly, R. & Mechta-Grigoriou, F. Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol. Rev. 302, 259–272 (2021).
pubmed: 34013544
pmcid: 8360036
doi: 10.1111/imr.12978
Lavie, D., Ben-Shmuel, A., Erez, N. & Scherz-Shouval, R. Cancer-associated fibroblasts in the single-cell era. Nat. Cancer 3, 793–807 (2022).
pubmed: 35883004
pmcid: 7613625
doi: 10.1038/s43018-022-00411-z
Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA. 110, 20212–20217 (2013).
pubmed: 24277834
pmcid: 3864274
doi: 10.1073/pnas.1320318110
Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
pubmed: 29443960
pmcid: 6028240
doi: 10.1038/nature25501
Krishnamurty, A. T. et al. LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 611, 148–154 (2022).
pubmed: 36171287
pmcid: 9630141
doi: 10.1038/s41586-022-05272-1
Pietras, K. & Ostman, A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316, 1324–1331 (2010).
pubmed: 20211171
doi: 10.1016/j.yexcr.2010.02.045
Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015).
pubmed: 26493647
pmcid: 4892184
doi: 10.1038/nrc4019
Nwani, N. G., Sima, L. E., Nieves-Neira, W. & Matei, D. Targeting the Microenvironment in High Grade Serous Ovarian Cancer. Cancers (Basel) 10, 266 (2018).
pubmed: 30103384
doi: 10.3390/cancers10080266
Su, S. et al. CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell 172, 841–856.e816 (2018).
pubmed: 29395328
doi: 10.1016/j.cell.2018.01.009
Glasgow, M. A. et al. Biological Insights into Chemotherapy Resistance in Ovarian Cancer. Int. J. Mol. Sci. 20, 2131 (2019).
Vienot, A. et al. Chemokine switch regulated by TGF-beta1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy. Oncoimmunology 11, 2144669 (2022).
pubmed: 36387055
pmcid: 9662195
doi: 10.1080/2162402X.2022.2144669
Zhang, J., Chen, M., Fang, C. & Luo, P. A cancer-associated fibroblast gene signature predicts prognosis and therapy response in patients with pancreatic cancer. Front. Oncol. 12, 1052132 (2022).
pubmed: 36465388
pmcid: 9716208
doi: 10.3389/fonc.2022.1052132
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L. & Montz, F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20, 1248–1259 (2002).
pubmed: 11870167
doi: 10.1200/JCO.2002.20.5.1248
Eng, K. H., Hanlon, B. M., Bradley, W. H. & Szender, J. B. Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. Gynecol. Oncol. 139, 228–235 (2015).
pubmed: 26383827
pmcid: 4630152
doi: 10.1016/j.ygyno.2015.09.011
Mikula-Pietrasik, J. et al. Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells. Cell Mol. Life Sci. 76, 681–697 (2019).
pubmed: 30382284
doi: 10.1007/s00018-018-2954-1
Zhang, K. et al. Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. Sci. Adv. 8, eabm1831 (2022).
pubmed: 35196078
pmcid: 8865800
doi: 10.1126/sciadv.abm1831
Bassez, A. et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med. 27, 820–832 (2021).
pubmed: 33958794
doi: 10.1038/s41591-021-01323-8
Kotliar, D. et al. Identifying gene expression programs of cell-type identity and cellular activity with single-cell RNA-Seq. Elife 8, e43803 (2019).
pubmed: 31282856
pmcid: 6639075
doi: 10.7554/eLife.43803
Chu, T., Wang, Z., Pe’er, D. & Danko, C. G. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. Nat. Cancer 3, 505–517 (2022).
pubmed: 35469013
pmcid: 9046084
doi: 10.1038/s43018-022-00356-3
Kleshchevnikov, V. et al. Cell2location maps fine-grained cell types in spatial transcriptomics. Nat. Biotechnol. 40, 661–671 (2022).
pubmed: 35027729
doi: 10.1038/s41587-021-01139-4
Garcia-Alonso, L., Holland, C. H., Ibrahim, M. M., Turei, D. & Saez-Rodriguez, J. Benchmark and integration of resources for the estimation of human transcription factor activities. Genome Res. 29, 1363–1375 (2019).
pubmed: 31340985
pmcid: 6673718
doi: 10.1101/gr.240663.118
Palla, G. et al. Squidpy: a scalable framework for spatial omics analysis. Nat. Methods 19, 171–178 (2022).
pubmed: 35102346
pmcid: 8828470
doi: 10.1038/s41592-021-01358-2
McCluggage, W. G. et al. Morphological effects of chemotherapy on ovarian carcinoma. J. Clin. Pathol. 55, 27–31 (2002).
pubmed: 11825920
pmcid: 1769574
doi: 10.1136/jcp.55.1.27
Sonnenberg, M. et al. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer 8, 364 (2008).
pubmed: 19077243
pmcid: 2626600
doi: 10.1186/1471-2407-8-364
Lotti, F. et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J. Exp. Med. 210, 2851–2872 (2013).
pubmed: 24323355
pmcid: 3865474
doi: 10.1084/jem.20131195
Hwang W. L. et al. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment. bioRxiv, 2020.2008.2025.267336 (2020).
Nicolas, A. M. et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell 40, 168–184.e113 (2022).
pubmed: 35120600
doi: 10.1016/j.ccell.2022.01.004
Cui Zhou D. Spatial drivers and pre-cancer populations collaborate with the microenvironment in untreated and chemo-resistant pancreatic cancer. bioRxiv, (BioRxiv).
Maia, A. et al. IFNbeta1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment. Mol. Oncol. 15, 1308–1329 (2021).
pubmed: 33476079
pmcid: 8096792
doi: 10.1002/1878-0261.12905
Shia, J. et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am. J. Surg. Pathol. 28, 215–223 (2004).
pubmed: 15043311
doi: 10.1097/00000478-200402000-00009
Saigusa, S. et al. Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. Int J. Oncol. 38, 655–663 (2011).
pubmed: 21240461
doi: 10.3892/ijo.2011.906
Nakasone, E. S. et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488–503 (2012).
pubmed: 22516258
pmcid: 3332002
doi: 10.1016/j.ccr.2012.02.017
Sun, Y. et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18, 1359–1368 (2012).
pubmed: 22863786
pmcid: 3677971
doi: 10.1038/nm.2890
Peiris-Pages, M., Sotgia, F. & Lisanti, M. P. Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. Oncotarget 6, 10728–10745 (2015).
pubmed: 25915429
pmcid: 4484415
doi: 10.18632/oncotarget.3828
Verset, L. et al. Impact of neoadjuvant therapy on cancer-associated fibroblasts in rectal cancer. Radiother. Oncol. 116, 449–454 (2015).
pubmed: 26021554
doi: 10.1016/j.radonc.2015.05.007
Woolston, A. et al. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell 36, 35–50.e39 (2019).
pubmed: 31287991
pmcid: 6617392
doi: 10.1016/j.ccell.2019.05.013
Mhaidly, R. & Mechta-Grigoriou, F. Inflammatory fibroblasts make rectal cancer resistant to radiation therapy. Cancer Cell 40, 122–124 (2022).
pubmed: 35120597
doi: 10.1016/j.ccell.2022.01.005
Hellevik, T. et al. Changes in the Secretory Profile of NSCLC-Associated Fibroblasts after Ablative Radiotherapy: Potential Impact on Angiogenesis and Tumor Growth. Transl. Oncol. 6, 66–74 (2013).
pubmed: 23418618
pmcid: 3573655
doi: 10.1593/tlo.12349
Katayama, M. L. H. et al. Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Cells 8, 1566 (2019).
pubmed: 31817155
pmcid: 6953077
doi: 10.3390/cells8121566
Li, Y. et al. Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells. Cancer Lett. 497, 212–220 (2021).
pubmed: 33132120
doi: 10.1016/j.canlet.2020.10.032
Dieci, M. V. et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann. Oncol. 25, 611–618 (2014).
pubmed: 24401929
pmcid: 3933248
doi: 10.1093/annonc/mdt556
Pozzi, C. et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat. Med. 22, 624–631 (2016).
pubmed: 27135741
doi: 10.1038/nm.4078
Wang, W. et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 165, 1092–1105 (2016).
pubmed: 27133165
pmcid: 4874853
doi: 10.1016/j.cell.2016.04.009
Pelekanou, V. et al. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res. 19, 91 (2017).
pubmed: 28784153
pmcid: 5547502
doi: 10.1186/s13058-017-0884-8
Jimenez-Sanchez, A. et al. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat. Genet. 52, 582–593 (2020).
pubmed: 32483290
pmcid: 8353209
doi: 10.1038/s41588-020-0630-5
Dauer, P. et al. Inactivation of cancer-associated-fibroblasts disrupts oncogenic signaling in pancreatic cancer cells and promotes its regression. Cancer Res. 78, 1321–1333 (2018).
pubmed: 29259015
doi: 10.1158/0008-5472.CAN-17-2320
Laklai, H. et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat. Med. 22, 497–505 (2016).
pubmed: 27089513
pmcid: 4860133
doi: 10.1038/nm.4082
Tauriello, D. V. F. et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538–543 (2018).
pubmed: 29443964
doi: 10.1038/nature25492
Desbois, M. et al. Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nat. Commun. 11, 5583 (2020).
pubmed: 33149148
pmcid: 7642433
doi: 10.1038/s41467-020-19408-2
Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 15, 637–646 (2013).
pubmed: 23708000
doi: 10.1038/ncb2756
Chen, Q. et al. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. 28, 432–437 (2014).
pubmed: 24589775
pmcid: 3950341
doi: 10.1101/gad.233676.113
Zanconato, F., Cordenonsi, M. & Piccolo, S. YAP/TAZ at the Roots of Cancer. Cancer Cell 29, 783–803 (2016).
pubmed: 27300434
pmcid: 6186419
doi: 10.1016/j.ccell.2016.05.005
Zanconato, F., Battilana, G., Cordenonsi, M. & Piccolo, S. YAP/TAZ as therapeutic targets in cancer. Curr. Opin. Pharm. 29, 26–33 (2016).
doi: 10.1016/j.coph.2016.05.002
Hall, C. A. et al. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 70, 8517–8525 (2010).
pubmed: 20947521
pmcid: 2970655
doi: 10.1158/0008-5472.CAN-10-1242
Ni, X. et al. YAP Is essential for treg-mediated suppression of antitumor immunity. Cancer Discov. 8, 1026–1043 (2018).
pubmed: 29907586
pmcid: 6481611
doi: 10.1158/2159-8290.CD-17-1124
Lebid, A., Chung, L., Pardoll, D. M. & Pan, F. YAP Attenuates CD8 T cell-mediated anti-tumor response. Front. Immunol. 11, 580 (2020).
pubmed: 32322254
pmcid: 7158852
doi: 10.3389/fimmu.2020.00580
Ferrari, N. et al. Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. Nat. Commun. 10, 130 (2019).
pubmed: 30631061
pmcid: 6328607
doi: 10.1038/s41467-018-07987-0
Szelachowska, J. et al. The effect of YAP expression in tumor cells and tumor stroma on the prognosis of patients with squamous cell carcinoma of the oral cavity floor and oral surface of the tongue. Oncol. Lett. 18, 3561–3570 (2019).
pubmed: 31579068
pmcid: 6757271
Shen, T. et al. YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression. J. Exp. Clin. Cancer Res. 39, 36 (2020).
pubmed: 32066485
pmcid: 7027236
doi: 10.1186/s13046-020-1542-z
Grunwald, B. T. et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell 184, 5577–5592 e5518 (2021).
pubmed: 34644529
doi: 10.1016/j.cell.2021.09.022
Kuhn, E., Kurman, R. J. & Shih, I. M. Ovarian cancer is an imported disease: fact or fiction? Curr. Obstet. Gynecol. Rep. 1, 1–9 (2012).
pubmed: 22506137
pmcid: 3322388
doi: 10.1007/s13669-011-0004-1
Meinhold-Heerlein, I. et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch. Gynecol. Obstet. 293, 695–700 (2016).
pubmed: 26894303
doi: 10.1007/s00404-016-4035-8
Duska, L. R. & Kohn, E. C. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann. Oncol. 28, viii8–viii12 (2017).
pubmed: 29232468
pmcid: 6246280
doi: 10.1093/annonc/mdx445
Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).
pubmed: 29203879
pmcid: 5715110
doi: 10.1038/s41598-017-17204-5
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
pubmed: 22743772
doi: 10.1038/nmeth.2019
Gueguen, P. et al. Contribution of resident and circulating precursors to tumor-infiltrating CD8(+) T cell populations in lung cancer. Sci. Immunol. 6, eabd5778 (2021).
pubmed: 33514641
doi: 10.1126/sciimmunol.abd5778
Naba, A. et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell Proteom. 11, M111 014647 (2012).
doi: 10.1074/mcp.M111.014647